PD-1+ polyfunctional T cells dominate the periphery after tumor-infiltrating lymphocyte therapy for cancer

Infusion of highly heterogeneous populations of autologous tumor-infiltrating lymphocytes (TILs) can result in tumor regression of exceptional duration. Initial tumor regression has been associated with persistence of tumor-specific TILs one month after infusion, but mechanisms leading to long-lived memory responses are currently unknown. Here we studied the dynamics of bulk tumor-reactive CD8+ T cell populations in patients with metastatic melanoma following treatment with TILs. Experimental Design: We analyzed the function and phenotype of tumor-reactive CD8+ T cells contained in serial blood samples of sixteen patients treated with TILs. Results: Polyfunctional tumor-reactive CD8+ T cells accumulated over time in the peripheral lymphocyte pool. Combinatorial analysis of multiple surface markers (CD57, CD27, CD45RO, PD-1 and LAG-3) showed a unique differentiation pattern of polyfunctional tumor-reactive CD8+ T cells, with highly specific PD-1 upregulation early after infusion. The differentiation and functional status appeared largely stable for up to 1 year post-infusion. Despite some degree of clonal diversification occurring in vivo within the bulk tumor-reactive CD8+ T cells, further analyses showed that CD8+ T cells specific for defined tumor-antigens had similar differentiation status. Conclusions: We demonstrated that tumor-reactive CD8+ T cell subsets which persist after TIL therapy are mostly polyfunctional, display a stable partially differentiated phenotype and express high levels of PD-1. These partially differentiated PD-1+ polyfunctional TILs have a high capacity for persistence and may be susceptible to PD-L1/PD-L2-mediated inhibition.

General information
Publication status: Published
Organisations: National Veterinary Institute, T-cells & Cancer, University of Warwick, University of Copenhagen, Cardiff University
Pages: 5779-5788
Publication date: 2017
Peer-reviewed: Yes

Publication information
Journal: Clinical Cancer Research
Volume: 23
Issue number: 19
ISSN (Print): 1078-0432
Ratings:
BFI (2017): BFI-level 2
Scopus rating (2017): CiteScore 8.38 SJR 4.929 SNIP 1.904
Web of Science (2017): Impact factor 10.199
Web of Science (2017): Indexed yes
Original language: English
Electronic versions:
CCR_1078_0432.CCR_16_1692.full.pdf
DOIs: 10.1158/1078-0432.CCR-16-1692
Source: FindIt
Source-ID: 2372244097
Research output: Contribution to journal › Journal article – Annual report year: 2017 › Research › peer-review